Roland Perry

About the Author Roland Perry

We are headquartered at the old Chicago Stock Exchange next to the Board of Trade, the Mercantile Exchange, The CBOE and Ceres, with offices in Beverly Hills CA and Port Jefferson NY. We work with small-cap companies which have products or services which can be defined as "best of breed." To align ourselves with shareholders, we typically seek to have 90% of our retainer, represented by an equity stake in our client companies. We additionally manage the Internet Stock Review, the Biotech Stock Review, and twelve others.

Top 20 Biotech Stocks for 2015.

Chicago IL / Research Report Wire / February 27th, 2015 / Institutional Analyst Inc.(IA) announced today it released the its Top 20 Biotech Watchlist for 2015.

IA is an independent investment research firm founded in 1998, with the launch of the “Internet Stock Review” and additionally provides coverage for companies in a number of distinct industries including; Beverages, Stem Cells, Internet, Patent Monetization, Alternative Energy, Entertainment, Restaurants, Special Situations and Private Equity.

“Our research efforts for 2015 are hard to categorize, beyond stating the names in our list are far from familiar and even for the biotech industry, inherently speculative. Price range from as low as $0.14 for Innovus Pharmaceutical $INNV, to as high at $29 for Cellular Biomedicine $CBMG, which we added to the list earlier in the year at $16. Market capitalizations excluding convertible debt, range from as small as $9 million for VirtualSopics $VSCP to as large as $400 million for Inovio Pharmaceutical $INO. If there is a theme in hindsight, it may be that many of the companies on the list are trading considerably off their trailing 12 month highs, versus breaking to new highs. In addition each possess compelling technology which we feel is best-of-breed, in light of their current stage of development.

The Biotech Stock Review was created as a starting point to help those investors searching for lower priced and smaller capitalization companies. Combined, the companies in the Watch List wouldn’t match the capitalization of a single biotech company, amongst Wall Street’s Top 25. Our proprietary database of publicly traded companies on Wall Street exceeds 200 names and is growing daily with the addition of smaller unheard of companies, who are with increasing frequency choosing to go public via a reverse merger or S-1 filings. This makes many of the companies much more difficult to find on a crowded Wall Street – versus companies which go public with a well publicized traditional IPO. The list is not a recommended list.

Top 20 Biotech Stocks for 2015.

Aethlon Medical, Inc. (AEMD) $0.18
*Apricus Biosciences, Inc (APRI) $2.43
Arrowhead Research Corp. (ARWR) $7.73
Atossa Genetics, Inc. (ATOS) $1.63
*Aeterna Zentaris Inc. (AEZS) $0.63
Adamis Pharmaceuticals Corporation (ADMP) $6.41
Biocept, Inc. (BIOC) $3.39
Bio-AMD, Inc. (BIAD) $0.22
Can-Fite BioPharma Ltd. (CANF) $4.06
*Cellular Biomedicine Group Inc. (CBMG) $28.46
Cellular Dynamics International, Inc. (ICEL) $5.11
Inovio Pharmaceuticals, Inc. (INO) $6.45
Innovus Pharmaceuticals, Inc. (INNV) $0.20
Neothetics, Inc. (NEOT) $6.80
NeuroMetrix Inc. (NURO) $1.68
Oculus Innovative Sciences, Inc. (OCLS) $0.79
Oncothyreon Inc (ONTY) $1.60
Ruthigen, Inc. (RTGN) $4.02
Sunesis Pharmaceuticals, Inc. (SNSS) $2.32
Tribute Pharmaceuticals Canada Inc. (TBUFF) $0.62
Tonix Pharmaceuticals Holding Corp (TNXP) $6.10
VirtualScopics Inc. (VSCP) $3.39

Aethlon Medical, Inc. ($AEMD) $0.18
Aethlon Medical, Inc. operates as a medical device company, which focuses on creating devices for the treatment of cancer, infectious diseases, and other life-threatening conditions. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The company’s Aethlon Hemopurifier is intended for the treatment of antiviral drug-resistance in hepatitis-C virus and human immunodeficiency virus infected individuals; serves as a countermeasure against viral pathogens not addressed by drug or vaccine therapies; and represents the therapeutic strategy to address cancer promoting exosomes. It also develops exosome-based products to diagnose and monitor cancer, infectious diseases, and neurological disorders; and is developing a medical device to reduce the incidence of sepsis in combat-injured soldiers.

Apricus Biosciences, Inc ($APRI) $2.43
Apricus Biosciences, Inc. is a biopharmaceutical company advancing medicines in urology and rheumatology. Its lead product, Vitaros, for the treatment of erectile dysfunction, is approved in Europe and Canada and is being commercialized in various countries in Europe. The company’s marketing partners for Vitaros include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A., and Laboratoires Majorelle. Its products under development include second-generation Vitaros Room Temperature Device; and RayVa, a product candidate, which is in Phase 2a trial, for the treatment of the circulatory disorder Raynaud’s phenomenon. The company also plans to initiate a Phase 2b trial for fispemifene, a selective estrogen receptor modulator for the treatment of male secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms. In addition, it is seeking a strategic partner to fund the development of Femprox, a product candidate for the treatment of female sexual interest/arousal disorder that has completed an approximately 400-subject proof-of-concept study.

Arrowhead Research Corp. ($ARWR) $7.73
Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company’s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its platform technology include Dynamic Polyconjugate platform, an RNAi delivery system that addresses multiple organ systems and cell types. The company is also involved in the development of Adipotide, which is in phase I clinical trial for the treatment of obesity and metabolic disorders; and CRLX-101 that is in phase II clinical trial to treat various cancer types, including relapsed renal cell carcinoma, relapsed ovarian cancer, and non-metastatic rectal cancer. It has research collaboration and license agreement with Shire AG to develop and commercialize targeted peptide-drug conjugates.

Atossa Genetics, Inc. ($ATOS) $1.63
Atossa Genetics Inc. operates as a healthcare company that focuses on the development of a suite of laboratory services, medical devices, and therapeutics for breast cancer in the United States. The company markets NAF cytology tests and pharmacogenomics tests. Its medical devices under development include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator devices that are intended for the collection of nipple aspirate fluid for cytological testing at a laboratory. The company is also involved in the development of other devices comprising intra ductal microcatheters for the collection of ductal lavage fluid and for the potential administration of a targeted therapeutic, as well as various tools for potential use by breast surgeons.

Aeterna Zentaris Inc. ($AEZS) $0.63
Aeterna Zentaris Inc., a specialty biopharmaceutical company, is focused on developing and commercializing novel treatments in oncology and endocrinology. The company’s product pipeline includes MACRILEN, for which a New Drug Application is under review by the FDA as an oral product used for evaluating adult growth hormone deficiency. MACRILEN is also investigated in a Phase 2A clinical trial to treat cancer-induced cachexia. Its product pipeline also comprises zoptarelin doxorubicin, which is in the ZoptEC (zoptarelin doxorubicin in Endometrial Cancer) Phase 3 trial in women with advanced, recurrent, or metastatic endometrial cancer. In addition, the company’s preclinical product candidates in oncology include AEZS-120, a live recombinant oral tumor vaccine candidate; PI3K/Erk inhibitors, including AEZS-129 and AEZS-136; and disorazol Z product candidates, such as AEZS-137 and AEZS-138.

Adamis Pharmaceuticals Corporation ($ADMP) $6.41
Adamis Pharmaceuticals Corporation, a biopharmaceutical company, is engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergies, oncology, and immunology. Its specialty pharmaceutical division has four products in its pipeline, including the Epinephrine Injection Pre-filled Syringe (PFS) for use in the emergency treatment of anaphylaxis; APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease (COPD); and APC-3000, a hydrofluoroalkane (HFA) inhaled nasal steroid product for the treatment of allergic rhinitis. The company’s biotechnology division focuses on the development of therapeutic vaccine product candidates and cancer drugs for patients with unmet medical needs in the global cancer markets. Its four products under development include TeloB-VAX, a novel cell-based therapeutic cancer vaccine for prostate cancer; and three drugs comprise APC-100, APC-200, and APC-300 for the treatment of prostate cancer.

Biocept, Inc. ($BIOC) $3.39
Biocept, Inc., a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA tests utilizing a standard blood sample. The company’s tests provide information to oncologists that enable them to select the appropriate treatment for their patients based on detailed data on the characteristics of tumors. It offers OncoCEE-BR, a breast cancer CTC test that allows physician to characterize the tumor to help define treatment options. The company is also developing other OncoCEE CTC tests, including OncoCEE-LU for lung cancer; OncoCEE-GA for gastric cancer; OncoCEE-CR for colorectal cancer; OncoCEE-PR for prostate cancer; and OncoCEE-ME for melanoma. Biocept, Inc. sells its products through its direct sales force and partners that focus on selling directly to community oncologists in hospitals, cancer centers, and offices in the United States, as well as biopharma companies. It has collaboration agreement with Rosetta Genomics, Ltd. to evaluate microRNAs from circulating tumor cells; and Insight Genetics to advance non-small cell lung cancer diagnosis and treatment.

Bio-AMD, Inc. ($BIAD) $0.22
Bio-AMD, Inc., a development stage company, through its subsidiary, Bio AMD Holdings Limited, focuses on developing hand held electronic medical diagnostic devices. It offers point of care (POC) medical diagnostic products, including a disposable micro-fluidic test strip to measure prothrombin time/international normalized ratio through a POC blood coagulation monitoring device that enables patient based, anticoagulant drug therapy monitoring; and a digital strip reader to read various lateral flow based immunoassay diagnostic test strips in the areas of cardiac markers, infectious diseases, drugs of abuse, and female wellbeing. The company also provides disposable test strip combining micro-fluidics and ‘lab-on-chip’ technology, which offers quantitative measurement into a immunoassay platform that detects nanoparticles through magnetic manipulation. In addition, Bio-AMD, Inc., through its subsidiary, WOCU Limited, develops WOCU, a foreign exchange derivative quotation to mitigate currency risk that would be licensed into various corporate and retail financial products, including exchange traded funds, indexed structured products, and derivatives.

Can-Fite BioPharma Ltd. ($CANF) $4.06
Can-Fite BioPharma, Ltd., a clinical-stage biotechnology company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and ophthalmic diseases. The company principally develops CF101 that is in Phase III study for the treatment of psoriasis, as well as completed Phase II study for the treatment of rheumatoid arthritis; completed Phase III study for the treatment of dry eye; completed Phase II study for the treatment of glaucoma; and initiating a Phase II study of CF101 for the treatment of uveitis. It also develops CF102, which is in Phase II study for the treatment of liver cancer; and CF602 that has completed pre-clinical trial for the treatment of inflammatory diseases. The company is headquartered in Petah-Tikva, Israel.

*Cellular Biomedicine Group Inc. ($CBMG) $28.46
Cellular Biomedicine Group, Inc., a biomedicine company, develops treatments for cancerous and degenerative diseases in Greater China. The company operates through two segments, Biomedicine and Consulting. It focuses on developing and marketing cell-based therapies to treat serious chronic and degenerative diseases, such as cancer, osteoarthritis, tissue damage, spinal muscular atrophy, various inflammatory diseases, and joint degeneration and metabolic diseases. The company develops treatments utilizing proprietary cell technologies comprising tumor cell specific dendritic cells for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint disease; human umbilical cord-derived mesenchymal progenitor cells; human embryo-derived motor neuron progenitor precursor cells; and human embryo-derived neuronal progenitor precursor cells for the treatment of central nervous system diseases. It also provides consulting services to companies who seek access to the U.S. capital markets.

Cellular Dynamics International, Inc. ($ICEL) $5.11
Cellular Dynamics International, Inc. develops and manufactures human cells in the United States of America, Europe, Japan, and internationally. The company’s proprietary iCell Operating System comprises human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs), and custom iPSCs and iCell products (MyCell products). It offers iCell Cardiomyocytes, which are purified human heart cells that beat in a dish and behave just like the heart cells found in the human body for in vitro drug discovery, toxicity testing, and chemical safety, as well as in vivo cellular therapeutics research and development, and stem cell banking; and iCell Neurons that are purified human neurons typical of the forebrain for pre-clinical drug discovery, neurotoxicity testing, and disease modeling for Alzheimer’s diseases, Parkinson’s diseases, Huntington’s diseases, and others. The company also provides iCell Endothelial cells, which are interior surface blood vessel cells for use in vascular biology research, such as angiogenesis, atherosclerosis, inflammation, and other life science research; and iCell Hepatocytes that are human liver cells for pre-clinical drug discovery, hepatotoxicity testing, disease modeling, and other life science research. In addition, it offers MyCell products for making iPSCs for stem cell banking, cell modeling of specific ethnic or disease populations, and genetic engineering for in vitro research; and media and reprogramming kits for making iPSCs for limited research use. The company serves biopharmaceutical companies, government research institutions, academic and nonprofit research institutions, contract research organizations, and stem cell banks.

Inovio Pharmaceuticals, Inc. ($INO) $6.45
Inovio Pharmaceuticals, Inc., together with its subsidiaries, discovers, develops, and develops synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The company’s DNA-based SynCon technology designed to provide protection against known and new unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company’s clinical programs include HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, and malaria vaccines. It is also advancing preclinical research for a seasonal/pandemic influenza vaccine, as well as other products.

Innovus Pharmaceuticals, Inc. ($INNV) $0.20
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men’s and women’s health and vitality. The Company generates revenues from its lead products Zestra(R) for female arousal and EjectDelay(R) for premature ejaculation and has a total of five marketed products in this space, including Sensum+(R) for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide(R), Vesele(R) for promoting sexual and cognitive health, Androferti(R) (in the US and Canada) to support overall male reproductive health and sperm quality and FlutiCare(TM) OTC for Allergic Rhinitis.

Neothetics, Inc. ($NEOT) $6.80
Neothetics, Inc., a clinical-stage specialty pharmaceutical company, engages in developing therapeutics for the aesthetic market. Its lead product candidate includes LIPO-202, an injectable formulation of salmeterol xinafoate that has completed Phase II development for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. The company is also developing LIPO-102 for the treatment of the orphan indication of symptomatic exophthalmos, or protrusion of the eye from the orbit, associated with thyroid-related eye disease caused by the expansion of fat and muscle behind the eye. The company was formerly known as Lipothera, Inc. and changed its name to Neothetics, Inc. in August 2014.

NeuroMetrix Inc. ($NURO) $1.68
NeuroMetrix, Inc., a medical device company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders, such as those associated with carpal tunnel syndrome, lumbosacral disc disease, spinal stenosis, and diabetes. The company focuses on the diagnosis and treatment of neurological complications of diabetes. Its marketed products include SENSUS pain therapy device, a transcutaneous electrical nerve stimulator used for chronic and intractable pain, such as painful diabetic neuropathy; NC-stat DPNCheck, a device used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy (DPN); and ADVANCE NCS/EMG system, a platform for the performance of traditional nerve conduction studies and invasive electromyography procedures for the assessment of carpal tunnel syndrome, low back and leg pain, and DPN, as well as consumables and accessories. The company distributes its products through its direct sales force and independent sales representatives to physicians, clinics, hospitals, managed care organizations, retail health businesses, and independent distributors consisting of primary care, internal medicine, orthopedic and hand surgeons, pain medicine physicians, neurologists, physical medicine and rehabilitation, physicians, and neurosurgeons, as well as endocrinology and podiatry markets primarily in the United States, Europe, Asia, and the Middle East.

Oculus Innovative Sciences, Inc. ($OCLS) $0.79
Oculus Innovative Sciences, Inc. designs, produces, and markets prescription and non-prescription products based on its Microcyn platform technology for the dermatology, surgical, advanced wound and tissue care, and animal healthcare markets in the United States, Mexico, Europe, and internationally. The Microcyn platform technology is based on electrically charged oxychlorine small molecules, which are designed to target a range of organisms that cause disease, including viruses, fungi, spores, and antibiotic-resistant strains of bacteria, such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus, as well as Clostridium difficile, a highly contagious bacteria spread by human contact. It offers Microcyn-based human advanced wound and tissue care products as prescription and over-the-counter products; and Microcyn technology-based animal healthcare products under the Vetericyn brand. The company’s Microcyn has received eight 510(k) clearances for use as a medical device in wound care management, including for acute and chronic wounds, and in dermatology applications. In addition, it provides consulting and laboratory services to medical companies that design and manufacture biomedical devices and drugs. Oculus Innovative Sciences, Inc. sells its products directly, and through contract sales organization and distributors to hospitals, physicians, nurses, and other healthcare practitioners, as well as to dermatologists for the treatment of various skin afflictions.

Oncothyreon Inc ($ONTY) $1.60
Oncothyreon Inc, a clinical-stage biopharmaceutical company, develops therapeutic products for the treatment of cancer. Its product candidate includes Tecemotide, a vaccine for the treatment of non-small cell lung cancer. The company is also developing ONT-10, a cancer vaccine, which is in Phase I clinical trial for use in various cancer indications, including breast, thyroid, colon, stomach, pancreas, ovarian, and prostate cancers, as well as various lung cancer; ONT-380, a small-molecule HER2 inhibitor that is in Phase Ib trial for the treatment of metastatic breast cancer, including patients with brain metastases; and PX-866, which has completed two Phase II trials for the treatment of various cancers. In addition, it develops PET lipid-A, a proprietary synthetic lipid-A analog.

Ruthigen, Inc. ($RTGN) $4.02
Ruthigen is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications. The company’s lead drug candidate, RUT58-60, is a broad-spectrum anti-infective that Ruthigen is developing for the prevention and treatment of infection in surgical and trauma procedures. The addressable market for RUT58-60 is approximately 30 million surgical and trauma procedures that are performed annually in the United States. The company’s clinical program targets an initial $700 million potential market in the prevention of infections associated with abdominal surgery, with the market for the prevention of infections associated with all types of surgery being estimated at $3 billion. Ruthigen plans to complete its Phase 1/2 clinical trial in Q1 2015 and, pending the successful completion of that trial, to conduct pivotal clinical trials.

Sunesis Pharmaceuticals, Inc. ($SNSS) $2.32
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company’s lead product candidate is vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia or AML. It has completed a Phase III, randomized, double-blind, placebo-controlled, and pivotal clinical trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AMl. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome. Sunesis Pharmaceuticals, Inc. has a collaboration agreement with Biogen Idec to discover, develop, and commercialize small molecule inhibitors of the human protein Raf kinase; and licensing agreements with Millennium to provide worldwide license to develop and commercialize preclinical inhibitors of PDK1.

Tribute Pharmaceuticals Canada Inc. ($TBUFF) $0.62
Tribute Pharmaceuticals Canada Inc., a specialty pharmaceutical company, is engaged in the acquisition, licensing, development, and promotion of healthcare products in Canada and internationally. The company focuses on various therapeutic areas, such as neurology, pain, urology, dermatology, and endocrinology/cardiology. Its products portfolio includes Cambia, a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks with or without aura in adults; and Bezalip SR (bezafibrate), a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia. The company also offers Soriatane (acitretin) for the treatment of severe psoriasis and other disorders of keratinization; and Collatamp G, a gentamicin-collagen haemostat for use as a surgical implant for haemostasis and local delivery of high doses of gentamicin. In addition, the company offers NeoVisc, a proprietary product for the temporary replacement of synovial fluid in osteoarthritic joints; and Uracyst, a sodium chondroitin sulfate solution for the treatment of interstitial cystitis and non-common cystitis. The company was formerly known as Stellar Pharmaceuticals, Inc. and changed its name to Tribute Pharmaceuticals Canada Inc. in January 2013.

Tonix Pharmaceuticals Holding Corp ($TNXP) $6.10
Tonix Pharmaceuticals Holding Corp., a development stage specialty pharmaceutical company, focuses on the identification and development of pharmaceutical products for the disorders of central nervous system. The company’s lead product candidate, TNX-102 sublingual tablet, is a dosage formulation of cyclobenzaprine for the treatment of fibromyalgia and post-traumatic stress disorder. It also has a pipeline of various other product candidates, including TNX-201, which is a treatment for certain types of episodic tension-type headache; and TNX-301 that is indicated for the treatment of alcohol abuse and dependence.

VirtualScopics Inc. ($VSCP) $3.39
VirtualScopics, Inc. (VSCP) is a leading provider of clinical trial imaging solutions to accelerate drug and medical device development. For risk-averse, time-constrained Clinical Trial Study Teams, Medical Directors and Imaging Scientists who require quality imaging data delivered on-time, within budget and on a consistent basis, VirtualScopics’ clinical trial imaging solutions are an inspired true exception to commonly accepted services provided by other clinical trial imaging providers. Because of the scientific and operational flexibility and responsiveness available, VirtualScopics’ clinical trial imaging solutions deliver special performance advantages compared to other image service providers that offer common, every day clinical trial imaging services.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts